Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 11/20 | 0.51 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | TTK | P33981 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL368114 | 0.88 | GRM4 (0.53) | GRM4GRM8KCNH2PDE4BMAPK14 | |
| SCHEMBL365856 | 0.86 | GRM4 (0.69) | GRM4GRM8KCNH2PDE4BKDR | |
| SCHEMBL370597 | 0.86 | GRM4 (0.57) | GRM4GRM8KCNH2KDR | |
| SCHEMBL367234 | 0.82 | GRM4 (0.74) | GRM4GRM8KCNH2KDR | |
| SCHEMBL12482364 | 0.82 | GRM4 (0.53) | GRM4GRM8KCNH2KDR | |
| SCHEMBL370591 | 0.78 | GRM4 (0.53) | GRM4GRM8KCNH2PDE4BMAPK14 | |
| SCHEMBL370788 | 0.76 | GRM4 (0.57) | GRM4GRM8KCNH2PDE4BKDR | |
| SCHEMBL369775 | 0.76 | GRM4 (0.69) | GRM4GRM8KCNH2PDE4BKDR | |
| SCHEMBL368073 | 0.76 | GRM4 (0.68) | GRM4KCNH2 | |
| SCHEMBL3359646 | 0.76 | GRM4 (0.41) | GRM4KCNH2PDE4BAURKACCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073907-B2 | Thiazoles derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMA S.A. (CH) | 2015-07-07 | — | — | US | claimed |
| EP-2376486-B1 | NOVEL THIAZOLES DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2013-11-06 | — | — | EP | claimed |
| US-20110257179-A1 | NOVEL THIAZOLES DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2011-10-20 | — | — | US | claimed |
| US-20110257179-A1 | NOVEL THIAZOLES DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257179-A1 | NOVEL THIAZOLES DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM4, GRM2, GRM1 | GRM4 1/4885GRM8 21/4885KCNH2 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.